Biotechnology Enzyme Engineering Articles & Analysis
12 news found
Watertown, MA — November 25, 2024—In the spirit of Thanksgiving, Biopharma PEG Scientific Inc. would like to express its sincere gratitude to our esteemed customers and partners for their trust and support. It is a privilege to collaborate with you, and we look forward to further strengthening our partnership in the future.As a gesture of our appreciation, we are pleased to announce a 30% ...
Recombinant indicates that this enzyme is produced using advanced biotechnological methods, specifically genetic engineering. ...
Profacgen, one of the leading biotechnology companies that provides first-class protein expression services, recently announced the release of multi-protein expression service in insect cells, to help scientists conduct protein co-expression network analysis and interaction studies. Multiprotein complexes are involved in a wide range of cellular processes, including transcription, translation, ...
Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, today announced it will present enhancements to its proprietary cytoDRIVE® technology during a poster presentation at the 25th ASGCT Annual Meeting. The conference is being hosted in Washington, D.C., and virtually, May 16-19, 2022. The data to be presented outline next-generation advancements ...
Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, today announced it will present preclinical data highlighting its cytoTIL15™ program during a poster session at the upcoming AACR Annual Meeting 2022. The abstract title has been posted to the AACR Online Itinerary Planner, will be published in the online Proceedings of the AACR, and is ...
Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, today announced it will present data highlighting the potential of the company’s cytoDRiVE® platform technology, which allows regulation of protein expression using small molecule drugs. The data to be presented demonstrate tight control of membrane bound or shed IL12 (a proinflammatory ...
Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent director, Cato T. Laurencin, M.D., Ph.D., to the company's Board of Directors. Dr. Laurencin is a distinguished university professor, award-winning engineer, orthopaedic surgeon, scientist, administrator, and pioneer in the field of regenerative engineering. Dr. Laurencin is actively involved in mentoring and social ...
ByAlkermes
Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, today announced that the Company will present preclinical in vivo anti-tumor efficacy against melanoma data for its cytoTIL15™ program at the upcoming Annual Meeting of the Society for Immunotherapy of Cancer (SITC). The event will be hosted live in Washington, D.C. and virtually from ...
Obsidian Therapeutics, a biotechnology company pioneering engineered cell and gene therapies, today announced that the Company will present data highlighting its cytoTIL15™ program at the upcoming European Society for Medical Oncology (ESMO) Congress, which will be hosted virtually September 16-21, 2021. The abstract for the poster describes how Obsidian’s cytoTIL15 product (TIL ...
Obsidian Therapeutics, a biotechnology company pioneering engineered cell and gene therapies, today announced that the Company will present at the upcoming 24th American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, which will be hosted virtually May 11-14, 2021. The abstract for the poster describes how Obsidian’s cytoTIL15 product (cytoTIL™ therapy engineered with ...
Multi-year strategic research collaboration leverages Obsidian’s proprietary cytoDRiVE® platform to discover controllable genetic therapies to treat serious diseases Vertex will pay Obsidian up to $75 million in equity, upfront payments and potential research milestones Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) and Obsidian Therapeutics announced today that the two ...
Dalent Medical, a Miami-based company developing innovative devices for Ear, Nose & Throat doctors is pleased to announce the closing of a $1.5 million funding round. The company has raised over $2 million from private investors since 2018. The additional funds will be used to produce inventory and ramp up sales & marketing to support the rollout of the company’s first patented ...